What is CAPR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.46B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CAPR?

P/E (TTM) is n/a and 52-week range is $2.96 to $40.37 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CAPR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CAPR?

The company profile lists revenue (TTM) near $22M, net income (TTM) near $-4.07B, EPS (TTM) near $-2.45 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Capricor Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 57.9M shares outstanding, ISIN US14070B3096 when available from company profile and filing metadata.

Capricor Therapeutics Inc

$CAPR

Health Care · Biotechnology

IR Run Scenarios

$7.83

-2.25%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California and currently employs 231 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

Employees

231

Website

capricor.com/

IPO

2002-06-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)